3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
5
Lung Neoplasms
2
Rhabdoid Tumor
1
Papillary renal cell carcinoma, sporadic
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Melanoma
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Hereditary leiomyomatosis and renal cell cancer
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Choroid Plexus Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma
1
Breast Neoplasms
1
Interventions
Oxaliplatin
8
Fluorouracil
8
pembrolizumab
7
Paclitaxel
6
Trastuzumab
5
Leucovorin
5
Capecitabine
5
Specimen Handling
4
Radiation
4
Cisplatin
4
Carboplatin
4
tislelizumab
3
patritumab deruxtecan
3
Taxes
3
Radiotherapy
3
Nivolumab
3
ulixertinib
2
trastuzumab deruxtecan
2
trastuzumab biosimilar HLX02
2
durvalumab
2
Surgical Procedures, Operative
2
Ramucirumab
2
Pemetrexed
2
PF-05280014
2
Ontruzant
2
Ogivri
2
Magnetic Resonance Spectroscopy
2
Irinotecan
2
Immunotherapy
2
Exercise
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
Erlotinib Hydrochloride
×
30 days
×
Clear all
No trials found.